Blood Tester Will Be Vindicated, Says Theranos Exec
The recent criticism surrounding Theranos, a privately held diagnostics company valued at about $9 billion, has been unfair, Theranos board member Richard Kovacevich said Monday.
He was responding to a series of Wall Street Journal reports raising questions about the accuracy of the proprietary method from Theranos — designed to conduct lab tests using only a small finger prick instead of drawing blood the traditional way with needles. The company stands by its claims, and CEO Elizabeth Holmes defended the work on CNBC in October.
He was responding to a series of Wall Street Journal reports raising questions about the accuracy of the proprietary method from Theranos — designed to conduct lab tests using only a small finger prick instead of drawing blood the traditional way with needles. The company stands by its claims, and CEO Elizabeth Holmes defended the work on CNBC in October.